89bio EBIT

89bio (ETNB) currently reports a EBIT of $-460M as of June 2025. That compares with $-190M in the prior-year period — down 139.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore 89bio's EBIT history and peer comparisons.

89bio's EBIT decreased from $-190M to $-460M — a 139.0% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

89bio's EBIT of $-460M is lower than the Healthcare sector average of $23B. That is roughly 102.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

89bio reported $-460M in EBIT as of June 2025. That compares with $-190M in the prior-year period — down 139.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-460M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for 89bio, and consider following ETNB for alerts when major investors trade the stock.